Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5221592 | 0.81 | SYK (0.48) | — | |
| SCHEMBL9629280 | 0.75 | MAPT (0.58) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL5065678 | 0.71 | GSK3B (0.52) | MAPK10MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5420895 | 0.68 | MAPK10 (0.50) | MAPK10MEN1KMT2ANPC1RAB9A | |
| SCHEMBL1460034 | 0.67 | CDC7 (0.56) | — | |
| SCHEMBL4803502 | 0.66 | MAP4K4 (0.65) | MAPK10CNR1KCNH2SCN5ASCN9A | |
| SCHEMBL4802429 | 0.66 | CYP1A2 (0.55) | MAPK10CNR1MAPK8ALDH1A1LMNA | |
| SCHEMBL5789745 | 0.66 | CDK4 (0.62) | MAPK10MEN1KMT2ANPC1RAB9A | |
| SCHEMBL21312135 | 0.65 | MAPK10 (0.64) | MAPK10MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4384008 | 0.64 | SYK (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318954-A1 | Compounds | CYCLACEL LIMITED (GB) | 2008-12-25 | — | — | US | claimed |
| EP-1751146-A2 | PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY | Cyclacel Limited (GB) | 2007-02-14 | — | — | EP | claimed |
| CN-1914199-A | Pyridyl or pyrimidyl thiazole compounds having protein kinase inhibitory activity | CYCLACEL LTD (GB) | 2007-02-14 | — | — | CN | claimed |
| WO-2005075468-A2 | PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY | CYCLACEL LIMITED (GB) | 2005-08-18 | — | — | WO | claimed |
| US-20080318954-A1 | Compounds | CYCLACEL LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20080318954-A1 | Compounds | CYCLACEL LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20080318954-A1 | Compounds | CYCLACEL LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| CN-1914199-A | Pyridyl or pyrimidyl thiazole compounds having protein kinase inhibitory activity | CYCLACEL LTD (GB) | 2007-02-14 | — | — | CN | disclosed |
| WO-2005075468-A2 | PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY | CYCLACEL LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318954-A1 | Compounds | CBR3, NR3C2, NR5A1 | MAPK10 2671/4885MEN1 1052/4885KMT2A 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.